UPDATE -- Bionano Genomics Announces its Support for the ACMG Foundation for Genetic and Genomic Medicine and its Next Generation Fellowship & Residency Training Awards Program
January 19 2022 - 10:50PM
Bionano Genomics, Inc. (BNGO), pioneer of optical genome mapping
(OGM) solutions on the Saphyr® system and provider of NxClinical™,
the leading software solutions for visualization, interpretation
and reporting of genomic data, today announced that it will
financially support the ACMG Foundation for Genetic and Genomic
Medicine and its Next Generation Fellowship & Residency
Training Awards Program in genetics and genomics.
Patients with genetic and genomic disorders require access to
medical professionals who are qualified to analyze and treat their
often extremely rare conditions. Due to shortages in medical
professionals in specialty areas of clinical genomics, it can be
difficult for a patient to connect with board-certified PhDs or MDs
in medical genetics and genomics. The Next Generation Fellowship
& Residency Training Awards Program has been helping fill that
gap for the past twenty years.
“As the chief executive officer for the ACMG Foundation for
Genetic and Genomic Medicine (ACMGF) and in support of the Next
Generation Fellowship & Residency Training Awards Program, I
want to personally thank and recognize Bionano Genomics. Their
generous commitment to three years of support for our Laboratory
Genetics and Genomics (LGG) fellowships will be critical to
bringing new talent to our specialty field. We believe Bionano’s
support will contribute to the future of clinical genomics, and I’m
glad that Bionano Genomics recognizes the importance of supporting
ACMGF and the program in laboratory genetic medicine,” said Dr. Max
Muenke, FACMG.
The Next Generation Fellowship & Residency Training Awards
Program is focused on expanding the workforce pipeline by
attracting excellent physicians and PhD laboratorians to genetic
and genomic medicine. Bionano’s three years of financial support in
this program is expected to play a significant role in the ACMGF’s
work to add more experts to the field and expand the reach of
genetic and genomic medicine.
“Bionano is honored and proud to support the ACMGF and the
laboratory geneticists who will be supported by these fellowships,”
commented Erik Holmlin, PhD, President and Chief Executive Officer
of Bionano. “Bionano’s mission is to transform the way the world
sees the genome so we can elevate the health and wellness of all
people. Supporting the development of the next generation of
leaders in the practice of laboratory genetic medicine through
the ACMGF Next Generation Fellowship & Residency Awards
Program is important in achieving that objective and we are
thankful to the ACMGF for the opportunity to be a part of
their efforts.”
About Bionano Genomics
Bionano Genomics is a provider of genome analysis solutions that
can enable researchers and clinicians to reveal answers to
challenging questions in biology and medicine. The Company’s
mission is to transform the way the world sees the genome through
OGM solutions, diagnostic services and software. The Company offers
OGM solutions for applications across basic, translational and
clinical research. Through its Lineagen business, the Company also
provides diagnostic testing for patients with clinical
presentations consistent with autism spectrum disorder and other
neurodevelopmental disabilities. Through its BioDiscovery business,
the Company also offers an industry-leading, platform-agnostic
software solution, which integrates next-generation sequencing and
microarray data designed to provide analysis, visualization,
interpretation and reporting of copy number variants,
single-nucleotide variants and absence of heterozygosity across the
genome in one consolidated view. For more information, visit
www.bionanogenomics.com, www.lineagen.com or
www.biodiscovery.com.
Forward-Looking Statements of Bionano
Genomics
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Words such as “may,” “will,” “expect,” “plan,” “anticipate,”
“estimate,” “intend” and similar expressions (as well as other
words or expressions referencing future events, conditions or
circumstances) convey uncertainty of future events or outcomes and
are intended to identify these forward-looking statements.
Forward-looking statements include statements regarding our
intentions, beliefs, projections, outlook, analyses or current
expectations concerning, among other things, the benefits of
Bionano’s support of ACMGF and its Next Generation Fellowship &
Residency Awards Program, Bionano’s anticipated role in advancing
ACMGF’s work and building the future of clinical genomics, and the
contributions of Bionano’s support toward bringing talent to the
clinical genomics field. Each of these forward-looking statements
involves risks and uncertainties. Actual results or developments
may differ materially from those projected or implied in these
forward-looking statements. Factors that may cause such a
difference include the risks and uncertainties associated with: the
impact of the COVID-19 pandemic on our business and the global
economy; general market conditions; changes in the competitive
landscape, including the introduction of competitive technologies
or improvements in existing technologies; failure of ACMGF or its
Next Generation Fellowship & Residency Awards Program to meet
expectations; changes in our strategic plans; our ability to obtain
sufficient financing to fund our strategic plans; and the risks and
uncertainties associated with our business and financial condition
in general, including the risks and uncertainties described in our
filings with the Securities and Exchange Commission, including,
without limitation, our Annual Report on Form 10-K for the year
ended December 31, 2020 and in other filings subsequently made by
us with the Securities and Exchange Commission. All forward-looking
statements contained in this press release speak only as of the
date on which they were made and are based on management’s
assumptions and estimates as of such date. We do not undertake any
obligation to publicly update any forward-looking statements,
whether as a result of the receipt of new information, the
occurrence of future events or otherwise.
CONTACTSCompany Contact:Erik Holmlin, CEOBionano Genomics,
Inc.+1 (858) 888-7610eholmlin@bionanogenomics.com
Investor Relations:Amy ConradJuniper Point+1 (858)
366-3243amy@juniper-point.com
Media Relations:Michael SullivanSeismic+1 (503)
799-7520michael@teamseismic.com
Bionano Genomics (NASDAQ:BNGO)
Historical Stock Chart
From Aug 2024 to Sep 2024
Bionano Genomics (NASDAQ:BNGO)
Historical Stock Chart
From Sep 2023 to Sep 2024